Completed PHASE2 INTERVENTIONAL 3-arm NCT00528905

Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia (HALO)

A Multi-Center Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase IIb Proof of Concept Study With 3 Oral Groups of AZD3480 During 12 Weeks Treatment of Cognitive Deficits in Patients With Schizophrenia

Sponsor: AstraZeneca

Conditions Schizophrenia

Interventions AZD3480

Updated 7 times since 2017 Last updated: Nov 21, 2008 Started: Aug 31, 2007 Primary completion: Oct 31, 2008 Completion: Nov 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00528905, this PHASE2 trial focuses on Schizophrenia and remains completed. Sponsored by AstraZeneca, it has been updated 7 times since 2007, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Allentown, United States , Anaheim, United States , Atlanta, United States , Augusta, United States , Austin, United States , Boca Raton, United States , Brooklyn, United States , Burlington, Canada , Calgary, Canada , Cedarhurst, United States and 70 more locations